Stock Market & Financial Investment News

News Breaks March 1, 2013 15:10 EDT BMY, SHPG Shire volatility flat; shares at record on Bristol-Myers had weighed acquisition Shire (SHPG) March call option implied volatility is at 29, April is at 28, July is at 25; compared to its 26-week average of 28 according to Track Data, suggesting non-directional price movement on Bristol-Myers (BMY) considering the company as a possible acquisition, WSJ says. News For BMY;SHPG From The Last 14 Days Check below for free stories on BMY;SHPG the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 13:21 EDT BMY Options with increasing implied volatility: CPRT BMY GDI HNZ Subscribe for More Information May 16, 2013 16:32 EDT BMY Bristol-Myers announces intention to voluntarily delist preferred stock Subscribe for More Information 13:20 EDT BMY Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. 13:14 EDT BMY Bristol-Myers upgraded to Outperform from Market Perform at Leerink Subscribe for More Information 08:55 EDT BMY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:38 EDT BMY Bristol-Myers shares likely to give back recent gains, says Leerink Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. 05:52 EDT BMY Stocks with implied volatility movement; BMY SLV Subscribe for More Information May 15, 2013 11:28 EDT BMY Options with increasing implied volatility: BMY AGNC EBIX IAU Subscribe for More Information 09:43 EDT BMY Active equity option families trading on open Subscribe for More Information May 14, 2013 07:24 EDT SHPG, BMY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 10, 2013 11:48 EDT BMY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 10:00 EDT SHPG On The Fly: Analyst Downgrade Summary Subscribe for More Information 05:42 EDT SHPG Shire downgraded to Neutral from Overweight at JPMorgan May 9, 2013 12:24 EDT SHPG Shire unit wins patent trial against Watson regarding LIALDA Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. 10:17 EDT BMY, SHPG Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information May 8, 2013 10:33 EDT BMY Bristol-Myers, Pfizer announced results from ARISTOTLE trial subanalysis Bristol-Myers (BMY) and Pfizer (PFE) announced yesterday that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from the subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. This story corrects a headline from yesterday. May 6, 2013 17:03 EDT BMY Bristol-Myers, Pfizer announce publication of ARISTOTLE trial Bristol-Myers Squibb (BMY) and Pfizer (PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation. Based on the results of the subanalysis, the benefits of Eliquis compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' quality of INR control. 08:53 EDT BMY BofA/Merrill's major pharma analysts hold an analyst/industry conference call Subscribe for More Information 07:27 EDT BMY Bristol-Myers, AstraZeneca announces results of metreleptin study Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.